charles shepherd
Senior Member
- Messages
- 2,239
PACE trial re-analysis and the 2007 NICE guideline on ME/CFS
For the benefit of people who are now querying what effect this paper will have on the calls to immediately revise the NICE guideline on ME/CFS - the answer at the moment is probably 'very little'
This is a preliminary report
If a further more detailed re-analysis and report confirms these findings, AND this gains the endorsement of yet more reputable members of the research community, then NICE will have to take serious note of the findings
Remember - the 2007 NICE guideline recommendations on CBT and GET were based on results from ALL the clinical trials prior to 2007 involving these interventions
The PACE trial results had not been published in 2007
When the results did appear in 2011 in The Lancet:
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60096-2/abstract
…..NICE just took the view that they added further support to what the NICE guideline was already recommending about the use of CBT and GET in mild and moderate cases of ME/CFS
In the meantime, the pressure on NICE is continuing and they are being informed about these developments
And this is the latest position (September 2016) that we have from NICE:
Re NICE clinical guideline chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management (CG53).
With regards to a potential review and update of the guideline, we currently expect to publish the review decision at the end of 2017. The review decision, once published, will outline whether NICE intends to update the guidance. We are committed to reviewing the guidance earlier than the original anticipated review date of 2019 and have brought this review date forward following information provided to NICE since the previous review took place. In accordance with our current schedule, it is unlikely that the review could take place any earlier than the end of 2017.
Details from the last formal (Forward ME Group) meeting with Professor Mark Baker from NICE and follow up with NHS England:
http://www.meassociation.org.uk/201...statement-by-the-me-association-10-july-2014/
http://www.meassociation.org.uk/201...heir-classification-of-mecfs-18-october-2014/
Dr Charles Shepherd
Hon Medical Adviser, MEA
For the benefit of people who are now querying what effect this paper will have on the calls to immediately revise the NICE guideline on ME/CFS - the answer at the moment is probably 'very little'
This is a preliminary report
If a further more detailed re-analysis and report confirms these findings, AND this gains the endorsement of yet more reputable members of the research community, then NICE will have to take serious note of the findings
Remember - the 2007 NICE guideline recommendations on CBT and GET were based on results from ALL the clinical trials prior to 2007 involving these interventions
The PACE trial results had not been published in 2007
When the results did appear in 2011 in The Lancet:
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60096-2/abstract
…..NICE just took the view that they added further support to what the NICE guideline was already recommending about the use of CBT and GET in mild and moderate cases of ME/CFS
In the meantime, the pressure on NICE is continuing and they are being informed about these developments
And this is the latest position (September 2016) that we have from NICE:
Re NICE clinical guideline chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management (CG53).
With regards to a potential review and update of the guideline, we currently expect to publish the review decision at the end of 2017. The review decision, once published, will outline whether NICE intends to update the guidance. We are committed to reviewing the guidance earlier than the original anticipated review date of 2019 and have brought this review date forward following information provided to NICE since the previous review took place. In accordance with our current schedule, it is unlikely that the review could take place any earlier than the end of 2017.
Details from the last formal (Forward ME Group) meeting with Professor Mark Baker from NICE and follow up with NHS England:
http://www.meassociation.org.uk/201...statement-by-the-me-association-10-july-2014/
http://www.meassociation.org.uk/201...heir-classification-of-mecfs-18-october-2014/
Dr Charles Shepherd
Hon Medical Adviser, MEA
Last edited: